PepGen (NASDAQ: PEPG) highlights DM1 splicing results in new data update

Rhea-AI Filing Summary

PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001835597 0001835597 2025-09-24 2025-09-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 24, 2025

PepGen Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41374		85-3819886
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

321 Harrison Avenue 8th Floor
Boston, Massachusetts		02118
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 781 797-0979

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		PEPG		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 24, 2025, PepGen Inc. (the “Company”) issued a press release titled “PepGen Announces Highest Mean Splicing Correction Ever Reported in DM1 Patients.” A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01, in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

A copy of the Company’s presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update”, is filed hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors from time to time.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release dated September 24, 2025
99.2		Freedom-DM1, 15 mg/gk Cohort Data Update Presentation, of September 2025
104		Cover page interactive data file (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						PEPGEN INC.
Date: September 24, 2025				By:		/s/ Noel Donnelly
						Noel Donnelly, Chief Financial Officer

FAQ

What did PepGen Inc. (PEPG) disclose in this 8-K filing?

PepGen Inc. disclosed that it issued a press release titled “PepGen Announces Highest Mean Splicing Correction Ever Reported in DM1 Patients” and furnished an investor presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update.”

How is the PepGen (PEPG) press release treated under SEC rules?

The press release furnished under Item 7.01, including Exhibit 99.1, is designated as “furnished” and not “filed” for purposes of Section 18 of the Exchange Act and is not subject to its liabilities on that basis.

What materials did PepGen (PEPG) attach as exhibits to this report?

PepGen attached Exhibit 99.1, the September 24, 2025 press release; Exhibit 99.2, the “Freedom-DM1, 15 mg/gk Cohort Data Update” presentation; and Exhibit 104, the cover page interactive data file.

How will PepGen (PEPG) use the Freedom-DM1 data update presentation?

PepGen stated that company representatives will use the “Freedom-DM1, 15 mg/gk Cohort Data Update” presentation in various meetings with investors from time to time.

When did the reported PepGen (PEPG) event occur?

The reported event occurred on September 24, 2025, which is the date PepGen issued the press release and the date of the report.

Who signed this PepGen (PEPG) 8-K on behalf of the company?

The report was signed on behalf of PepGen Inc. by Noel Donnelly, Chief Financial Officer, dated September 24, 2025.